Upgrade to SI Premium - Free Trial

Raymond James Reiterates Strong Buy Rating on Dyne Therapeutics (DYN)

March 25, 2026 3:21 PM
Raymond James analyst Michael Freeman reiterated a Strong Buy rating and $40.00 price target on Dyne Therapeutics (NASDAQ: DYN).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments